Proteon Therapeutics Inc. is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/16/14 | $45,000,000 | Series D |
Abingworth Deerfield Management Company, L.P. Pharmstandard International Vectis Healthcare and Life Sciences Fund | undisclosed |
